Phathom Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $587.07M
- P/E (TTM)
- –
- Dividend yield
- –
About Phathom Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to commercializing and developing therapeutic treatments for gastrointestinal diseases. The company offers vonoprazan-based acid blockers, including VOQUEZNA tablets for gastroesophageal reflux disease indications such as Erosive GERD and Non-Erosive GERD heartburn, as well as combination therapies for Helicobacter pylori infection alongside antibiotics under the brands VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK. Its primary customers are patients prescribed therapies for gastrointestinal conditions through healthcare providers such as gastroenterologists.
The enterprise operates as a single reporting segment centered on commercializing gastrointestinal therapies within the United States, while holding license rights covering European and Canadian markets. The company maintains commercial healthcare coverage spanning more than 120 million covered lives across America. Phathom Pharmaceuticals maintains its principal executive offices and headquarters in Florham Park, New Jersey.
Summary of the business section of Phathom Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Phathom Pharmaceuticals, Inc.
- Headquarters
- Florham Park, NJ
- Address
- 100 Campus Drive,, Suite 102 07932
- Phone
- (877) 742-8466
- Website
- phathompharma.com
- Employees
- 371, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- PHAT
- Exchange
- Nasdaq
- IPO date
- Oct 28, 2019
- Shares outstanding
- 81M, Jul 27, 2026
- Public float
- $555.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1783183
- CUSIP
- 71722W107
- ISIN
- US71722W1071
- EIN
- 82-4151574
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven L. Basta | President and CEO, Director | 373,315 |
| Terrie Curran | President and Chief Executive, Director | 364,305 |
| Robert Charles Breedlove | Principal Accounting Officer | 67,657 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 88,660 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 226,715 |
| Molly Henderson | CFO and CBO | 91,779 |
| Azmi Nabulsi | Chief Operating Officer | 1,101,869 |
| Asit Parikh | Director | 172,622 |
| Mark Stenhouse | Director | 54,122 |
| Frank Karbe | Director | 91,622 |
| James N. Topper | Director | 5,957,449 |
| Michael F. Cola | Director | 63,920 |
| Theodore R. Schroeder | Director | 45,122 |
| Heidi Fields | Director | 54,122 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steven Basta | $6.97M | $24.38M | $2.81M | $148 | – |
| FY2025 Terrie Curran | $4.94M | -$356.11K | $2.81M | $148 | – |
| FY2024 | $3.56M | $3.76M | $1.50M | $72 | – |
| FY2023 | $3.41M | $2.46M | $1.95M | $81 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 371 full-time employees, some of whom hold a Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 2, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 28, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 16, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |